Cataract surgery with premium intraocular lenses

All patients participating in the Programme will receive advanced ophthalmic investigations including optical coherence tomography (OCT) for a comprehensive diagnostic evaluation of the cornea, anterior chamber angle, macula, and optic disc for detection of eye diseases including glaucoma and age-related macular degeneration, in addition to cataract. Eligible patients will undergo unilateral cataract surgery with the implantation of a premium intraocular lens (IOL), including (1) trifocal IOL (providing clear vision at three distinct distances: near, intermediate, and far), (2) extended depth of focus IOL (providing clear vision over a continuous range of distance and intermediate vision), and (3) next-generation monofocal IOL with an extended depth of focus. All premium IOL models used in the Programme have been globally adopted and obtained approval from major regulatory bodies, including the US Food and Drug Administration. A subset of patients will be invited to participate in a research study and receive cataract surgery for both eyes. The study will compare the visual outcomes of implanting trifocal IOLs in both eyes versus implanting next-generation monofocal IOLs with monovision, using virtual reality simulation that mimics everyday activities to provide a realistic assessment of visual performance after the surgery. The intraocular lenses are in part provided by Johnson and Johnson Vision.

​

以新一代具有長景深的高質人工晶體進行白內障手術

患者將接受先進的眼科檢查，包括以光學相干斷層掃描（OCT）對角膜、前房角、黃斑和視神經盤進行高解像度的評估，以及檢測除白內障以外的眼部疾病，包括青光眼和老年黃斑退化。合資格的患者將接受單眼白內障手術，並植入具有長景深的新一代高質人工晶體（IOL）, 包括 （1）三焦點人工晶體（在近距離、中距離和遠距離均能提供清晰視覺）、（2）擴展景深人工晶體（在遠距離和中距離提供清晰視覺）和 （3）長景深單焦點人工晶體。計劃中使用的所有高質人工晶體型號已在全球廣泛使用，並獲得主要監管機構包括美國食品及藥物管理局的批准。部分患者將獲邀請參與研究計劃，並接受雙眼白內障手術。該研究將比較在雙眼植入三焦點人工晶體與植入具有長景深單焦點人工晶體後的視覺結果，使用日常活動的虛擬實景模擬，以提供對手術後視覺表現的評估。部分人工晶體由強生公司（Johnson and Johnson Vision） 提供。